Literature DB >> 23183056

Intrahepatic cholangiocarcinoma: impact of genetic hemochromatosis on outcome and overall survival after surgical resection.

Laurent Sulpice1, Michel Rayar, Eveline Boucher, Fabienne Pele, Marc Pracht, Bernard Meunier, Karim Boudjema.   

Abstract

BACKGROUND: The influence of genetic hemochromatosis (GH) on outcomes following surgical resections for intrahepatic cholangiocarcinoma (ICC) has not been evaluated.
METHODS: All patients with ICC who underwent a surgical resection between January 1997 and August 2011 were analyzed retrospectively. Risk factors were assessed by univariate and multivariate analyses.
RESULTS: Eighty-seven patients were analyzed; 16 of these patients (18.4%) had GH. Among the 71 non-GH patients, 52 (73.2%) and 19 (26.8%) had normal or cirrhotic parenchyma, respectively. There was no significant difference in survival between the GH and non-GH patients. A univariate analysis showed that major hepatectomy (P = 0.012), intraoperative blood transfusion (P = 0.007), tumor size >5 cm (P = 0.006), several nodules (P < 0.001), and microvascular invasion (P = 0.04) were significantly associated with poor survival. A multivariate analysis showed that intraoperative blood infusion (HR 0.37; CI 95% [0.19; 0.71]) and more than one nodule (HR 2.5; CI 95% [1.06; 5.8]) were associated with a lower survival rate.
CONCLUSION: Although the incidence of GH was high in our series, the presence of GH did not affect the outcomes after a liver hepatectomy for ICC. GH does not appear to increase recurrences or worsen the overall and disease-free survival.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23183056     DOI: 10.1016/j.jss.2012.10.051

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

Review 1.  Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review.

Authors:  Neda Amini; Aslam Ejaz; Gaya Spolverato; Shishir K Maithel; Yuhree Kim; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-10-10       Impact factor: 3.452

Review 2.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

3.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

Review 4.  An update on liver surgery for cholangiocarcinoma.

Authors:  Karim Boudjema; Giovanni Battista Levi Sandri; Eveline Boucher; Tanguy Rohou; Michel Rayar; Laurent Sulpice
Journal:  Updates Surg       Date:  2013-10-02

Review 5.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

6.  Evaluating a preoperative protocol that includes magnetic resonance imaging for lymph node metastasis in the Cholangiocarcinoma Screening and Care Program (CASCAP) in Thailand.

Authors:  Metha Songthamwat; Nittaya Chamadol; Narong Khuntikeo; Jadsada Thinkhamrop; Supinda Koonmee; Nathaphop Chaichaya; Jeffrey Bethony; Bandit Thinkhamrop
Journal:  World J Surg Oncol       Date:  2017-09-20       Impact factor: 2.754

Review 7.  Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Michele Ghidini; Antonio Ghidini; Giovanni Sgroi; Ivano Vavassori; Daniela Petrò; Mary Cabiddu; Alberto Aiolfi; Gianluca Bonitta; Alberto Zaniboni; Emanuele Rausa
Journal:  Surg Today       Date:  2021-01-03       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.